Bavarian Nordic (BAVA.CO)'s MVA-BN® Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development
2/21/2014 8:43:00 AM
KVISTGAARD, Denmark, February 21, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC:
BVNRY) announced today that its MVA-BN vaccine platform technology has been
selected by the Defense Threat Reduction Agency (DTRA), a part of the United
States Department of Defense, for the development of a vaccine against two
potential biological threats to national security - Burkholderia pseudomallei
and Burkholderia mallei.
Help employers find you! Check out all the jobs and post your resume.
comments powered by